 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2011;4(1):32-42
Review Article
Multimodality molecular imaging of CD105 (Endoglin) expression
Yin Zhang, Yunan Yang, Hao Hong, Weibo Cai
Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin, USA;
Department of Ultrasound, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P. R. China;
Department of Radiology, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin, USA;
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA.
Received December 21, 2010; accepted December 25, 2010; Epub December 26, 2010; published January 1, 2011
Abstract: Since most solid tumor growth depends on angiogenesis, non-invasive imaging of tumor angiogenesis can allow for much
earlier diagnosis and better prognosis of cancer, as well as more accurate treatment monitoring, which will eventually lead to
personalized molecular medicine. CD105, also known as endoglin, is required for endothelial cell proliferation. The currently accepted
standard method for quantifying tumor angiogenesis is to assess microvessel density based on CD105 staining, which has been
shown to be an independent prognostic factor for survival in patients of almost all solid tumor types. In this review, we will summarize
the progress to date on multimodality molecular imaging of CD105 expression during tumor angiogenesis which includes targeted
contrast-enhanced ultrasound, molecular magnetic resonance, near-infrared fluorescence, single-photon emission computed
tomography, and positron emission tomography. Although molecular imaging of CD105 expression is surprisingly understudied,
non-invasive imaging of CD105 expression has already been achieved with every single molecular imaging modality. In the future,
significant research effort should be directed towards non-invasive visualization of CD105 expression, such as quantitative imaging,
the use of long-lived isotopes for antibody-based imaging, development of peptide, small molecule, or antibody fragment-based
imaging agents, multimodality imaging of CD105 expression with a single agent, the application of nanotechnology, among others.
(IJCEM1012003).
Keywords: Tumor angiogenesis, CD105 (Endoglin), molecular imaging, positron emission tomography (PET), single-photon
emission computed tomography (SPECT), monoclonal antibody (mAb), cancer, anti-angiogenic therapy
Full Text PDF
Address all correspondence to:
Weibo Cai, PhD
Departments of Radiology and Medical Physics
School of Medicine and Public Health, University of Wisconsin
1111 Highland Ave, Room 7137, Madison, WI 53705-2275, USA.
Tel: 1-608-262-1749, Fax: 1-608-265-0614
Email: wcai@uwhealth.org.
Review Article
Multimodality molecular imaging of CD105 (Endoglin) expression
Yin Zhang, Yunan Yang, Hao Hong, Weibo Cai
Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin, USA;
Department of Ultrasound, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P. R. China;
Department of Radiology, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin, USA;
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA.
Received December 21, 2010; accepted December 25, 2010; Epub December 26, 2010; published January 1, 2011
Abstract: Since most solid tumor growth depends on angiogenesis, non-invasive imaging of tumor angiogenesis can allow for much
earlier diagnosis and better prognosis of cancer, as well as more accurate treatment monitoring, which will eventually lead to
personalized molecular medicine. CD105, also known as endoglin, is required for endothelial cell proliferation. The currently accepted
standard method for quantifying tumor angiogenesis is to assess microvessel density based on CD105 staining, which has been
shown to be an independent prognostic factor for survival in patients of almost all solid tumor types. In this review, we will summarize
the progress to date on multimodality molecular imaging of CD105 expression during tumor angiogenesis which includes targeted
contrast-enhanced ultrasound, molecular magnetic resonance, near-infrared fluorescence, single-photon emission computed
tomography, and positron emission tomography. Although molecular imaging of CD105 expression is surprisingly understudied,
non-invasive imaging of CD105 expression has already been achieved with every single molecular imaging modality. In the future,
significant research effort should be directed towards non-invasive visualization of CD105 expression, such as quantitative imaging,
the use of long-lived isotopes for antibody-based imaging, development of peptide, small molecule, or antibody fragment-based
imaging agents, multimodality imaging of CD105 expression with a single agent, the application of nanotechnology, among others.
(IJCEM1012003).
Keywords: Tumor angiogenesis, CD105 (Endoglin), molecular imaging, positron emission tomography (PET), single-photon
emission computed tomography (SPECT), monoclonal antibody (mAb), cancer, anti-angiogenic therapy
Full Text PDF
Address all correspondence to:
Weibo Cai, PhD
Departments of Radiology and Medical Physics
School of Medicine and Public Health, University of Wisconsin
1111 Highland Ave, Room 7137, Madison, WI 53705-2275, USA.
Tel: 1-608-262-1749, Fax: 1-608-265-0614
Email: wcai@uwhealth.org.
